Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 25, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2027

Conditions
Ovarian Cancer
Interventions
DRUG

Paclitaxel

"First-line chemotherapy regimen:~* Paclitaxel: 175 mg/m², intravenous infusion, on day 1.~* Carboplatin: AUC 5, intravenous infusion, on day 1.~* Surufatinib:250 mg once daily, taken continuously.~Maintenance Therapy Regimen:~* Surufatinib: 250 mg once daily, taken continuously.~* Olaparib: 300 mg twice daily."

Trial Locations (1)

230001

RECRUITING

Anhui Cancer Hospital, Hefei

All Listed Sponsors
collaborator

Hutchison Medipharma Limited

INDUSTRY

lead

Anhui Provincial Cancer Hospital

OTHER